In 2006, Huang et al. demonstrated for the first time the practicality of NIR PPTT, using AuNRs functionalized with anti-EGFR antibodies to specifically target EGFR-positive head and neck cancer cells in vitro [82] (Figure 3A). The gene discussed is EGFR; the disease is head and neck cancer.